ERBB2 and breast cancer: FASN may lead to herceptin resistance in breast cancer through at least two pathways: i) up-regulating PEA3 transcription to inhibit HER2 gene expression, and ii) changing the lipid composition and function of BCC membrane, thereby affecting the membrane localization of HER2.97